Oppenheimer Lowers TransMedics Group (NASDAQ:TMDX) Price Target to $125.00

TransMedics Group (NASDAQ:TMDX) had its price objective trimmed by Oppenheimer from $200.00 to $125.00 in a report released on Tuesday, MarketBeat reports. The firm currently has an outperform rating on the stock.

Several other equities research analysts also recently issued reports on the stock. Robert W. Baird initiated coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective for the company. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a research note on Monday, October 7th. Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, Stephens upped their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $144.80.

TransMedics Group Price Performance

TMDX stock opened at $82.40 on Tuesday. The stock has a 50-day moving average price of $140.51 and a two-hundred day moving average price of $139.29. The stock has a market cap of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. The company has a current ratio of 8.20, a quick ratio of 8.48 and a debt-to-equity ratio of 2.42. TransMedics Group has a 1 year low of $38.13 and a 1 year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. During the same quarter in the prior year, the company earned ($0.12) earnings per share. The company’s quarterly revenue was up 63.7% on a year-over-year basis. Equities analysts forecast that TransMedics Group will post 1.11 EPS for the current fiscal year.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $9,457,269.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the transaction, the director now owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,247 shares of company stock worth $9,518,181. Corporate insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TMDX. Amalgamated Bank lifted its holdings in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after purchasing an additional 70 shares during the period. Pitcairn Co. lifted its stake in shares of TransMedics Group by 1.5% in the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares in the last quarter. Harbour Capital Advisors LLC lifted its stake in shares of TransMedics Group by 1.7% in the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares in the last quarter. Signaturefd LLC raised its holdings in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.